Inflazyme Pharmaceuticals Ltd.
TSX : IZP

Inflazyme Pharmaceuticals Ltd.

May 11, 2006 17:00 ET

Inflazyme Announces Upcoming Presentation on IPL512,602 at the 2006 American Thoracic Society 'ATS' International Conference

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 11, 2006) - Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced that the results of the Phase IIa study of IPL512,602 in patients with mild-moderate persistent asthma will be presented at the 2006 American Thoracic Society (ATS) International Conference being held May 19-24, 2006 in San Diego, California. The title of the presentation is: The Effect of IPL512,602 in Patients with Mild-Moderate Persistent Asthma (NEAT Study).

The presentation details are as follows:



Session Date: Sunday, May 21, 2006
Session Time: 8:15 am - 4:15 pm
(Viewing Time: 10:45 am - 12:15 pm)
Abstract Number: 2248
Session Code: A106 - New Therapies for Asthma
Session Room: Area K (Sails Pavilion, Upper Level),
San Diego Convention Center


IPL512,602 is a first in class, once daily, oral anti-inflammatory drug that is being evaluated as a potential treatment for asthma. The presentation will summarize the efficacy and clinical benefit demonstrated by IPL512,602 in a placebo controlled, double-blind, parallel 12-week Phase IIa trial. This study was the first time the drug was evaluated in patients. The drug showed statistical significance in several key parameters of asthma control, namely, asthma quality of life, airway hyper-responsiveness and reduction in albuterol use. In addition to the efficacy measures, IPL512,602 was also found to be safe and well tolerated.

IPL512,602 has recently entered a Phase IIb clinical study in moderate to severe asthma patients called the Control of Asthma Patients Symptomatic on Inhaled Corticosteroids Study (CAPSICS) (see News Release dated May 9, 2006).

About Inflazyme

Inflazyme Pharmaceuticals is a biopharmaceutical company pioneering medical breakthroughs to transform the lives of patients with respiratory and inflammatory diseases worldwide. Further information on the Company may be obtained from its website at www.inflazyme.com.

Statements in this news release other than historical information are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Information Form for Inflazyme on file with the Canadian Securities Commissions.


The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

Contact Information